CTRC-AACR SABCS Annual Meeting

New Prognostic Tool to Guide Treatment of Ductal Carcinoma In Situ

Caroline Helwick

December 2011, Vol 2, No 7 - CTRC-AACR SABCS Annual Meeting

San Antonio, TX—The treatment of ductal carcinoma in situ (DCIS)— breast cancer confined to the ducts—is a clinical challenge, as patients carry varying risks of recurrence and may easily be undertreated or overtreated. But Genomic Health, which markets Oncotype DX for assessing risk of recurrence in invasive cancers, has developed a similar test for DCIS that may prove useful for individualizing treatment in this subset of breast cancer. The test is expected to become available for physicians for use on December 28, 2011.

[ Read More ]

Adding Everolimus to Exemestane Significantly Prolongs Remission in Patients with Breast Cancer

Caroline Helwick

December 2011, Vol 2, No 7 - CTRC-AACR SABCS Annual Meeting

San Antonio, TX—Updated results from the phase 3 Breast Cancer Trials of Oral Everolinmus (BOLERO-2) showed that adding everolimus to the treatment regimen with the aromatase inhibitor exemestane more than doubles the time to disease progression in patients with advanced estrogen receptor (ER)-positive breast cancer whose disease has become refractory to hormonal therapy.

[ Read More ]

Role of Adjuvant Zoledronic Acid in Endocrine Receptor- Positive Breast Cancer Being Refined

Phoebe Starr

December 2011, Vol 2, No 7 - CTRC-AACR SABCS Annual Meeting

San Antonio, TX—Mounting evidence from randomized controlled trials suggests that zoledronic acid added to hormonal therapy will have its optimal use as adjuvant therapy in postmenopausal women with either medically/ surgically induced menopause or age-related menopause. The results of 2 trials were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.

[ Read More ]

Dual HER2 Blockade with Pertuzumab Substantially Delays Disease Progression

Caroline Helwick

December 2011, Vol 2, No 7 - CTRC-AACR SABCS Annual Meeting

San Antonio, TX—It is becoming increasingly clear that 2 agents are better than 1 in treating HER2-positive advanced breast cancer.

The latest evidence comes from the results of the phase 3 clinical trial CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab), which were presented at the 2011 CTRC-AACR/San Antonio Breast Cancer Symposium by Jose Baselga, MD, PhD, Professor of Medicine, Harvard Medical School and Associate Director of the Massachusetts General Hospital Cancer Center, Boston.

[ Read More ]